VISTA Eye Specialist, a leading provider of comprehensive eye care and refractive surgery in Malaysia, has announced a transformative partnership with the PX Ninety program, led by renowned patient experience expert Shareef Mahdavi. This collaboration aligns with VISTA’s ambitious 2025 vision, “Ikigai WowX,” aimed at enhancing patient, employee, and community experiences in healthcare.
The PX Ninety program, designed to infuse empathy, communication, and personalization into every patient interaction, complements VISTA’s mission to go beyond clinical excellence. Under the guidance of Shareef Mahdavi, founder of the PX Movement and author of Beyond Bedside Manner, VISTA is taking significant strides in reshaping how healthcare is delivered.
“Healthcare is more than just outcomes—it’s about building meaningful connections that make a lasting impact,” said Mahdavi. “VISTA’s adoption of the PX Ninety program is a testament to their visionary leadership in patient care, integrating personalized attention with employee empowerment and community engagement.”
A New Era of Patient Experience
PX Ninety focuses on creating a healthcare environment that prioritizes emotional well-being alongside clinical needs. It complements VISTA’s Ikigai WowX philosophy, inspired by the Japanese concept of ikigai, which emphasizes purpose and fulfillment.
Carol Heng, Regional Center Manager at VISTA and Chief Experience Designer for the PX Ninety program, explained, “Our goal is to go beyond clinical excellence. With PX Ninety and Ikigai WowX, we are transforming eye care by creating experiences that are not just impactful but transformative.”
The program aims to shift VISTA’s organizational culture by empowering its Experience Designers to:
Elevate Patient Care: Ensuring every patient feels valued, understood, and inspired.
Empower Employees: Fostering a collaborative and purpose-driven workplace culture.
Impact Communities: Extending care beyond the clinic to enhance the lives of local communities.
Patient Experience: The Future of Healthcare
VISTA’s emphasis on patient experience reflects a broader industry trend where emotional well-being is becoming a key differentiator in healthcare. By focusing on how patients feel at every stage of their journey, VISTA seeks to create moments of joy and hope that transcend medical outcomes.
“Imagine a patient who has struggled with impaired vision for years suddenly seeing clearly for the first time,” said Bernard Chan, Training & Sustainability Manager at VISTA. “This isn’t just a medical result—it’s a life transformation. PX Ninety and Ikigai WowX empower us to celebrate these pivotal moments and inspire patients to live with renewed confidence.”
Leading Healthcare Innovation
This collaboration highlights VISTA’s role as a thought leader in the healthcare industry, setting a new standard for patient-centric care. By prioritizing patient experience, VISTA is not only improving healthcare outcomes but also fostering a culture of compassion, purpose, and meaningful impact.
“VISTA’s adoption of PX Ninety invites the healthcare industry to think bigger,” said Mahdavi. “It’s about making healthcare more human and more compassionate, ultimately making it more meaningful for everyone involved.”
About VISTA Eye Specialist
With 18 locations across Malaysia, VISTA Eye Specialist is known for its exceptional eye care services and commitment to clinical excellence. The organization leverages innovative technology and a patient-first approach to improve vision and enhance the well-being of its patients and communities.
About Shareef Mahdavi
Shareef Mahdavi is a globally recognized authority in patient experience and the founder of the PX Movement. Through the PX Ninety program, Mahdavi has helped healthcare organizations worldwide adopt patient-centric practices that improve care and drive sustainable growth. He is also the founder of SM2 Strategic, a consultancy specializing in healthcare transformation, and the author of Beyond Bedside Manner.
Related topic:
AOP Calls for Major Overhaul of Eye Care in NHS 10-Year Plan
NHS Approves Kimmtrak for Treating Uveal Melanoma
Gland Pharma Shares Surge After USFDA Approval for Eye Treatment
